BOTHELL, Wash., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the prevention of migraine, Congenital Adrenal Hyperplasia, Cushing’s Disease and autoimmune and inflammatory diseases, today provided a corporate update and reported its financial results for the fourth quarter and full year ended Dec. 31, 2015.
“Our focus this year remains on the accelerated development of ALD403, Alder’s pivotal-stage migraine prevention candidate with the potential to deliver migraine-free relief to patients living with migraine. Expected progress this year includes ongoing enrollment in our first pivotal trial, PROMISE 1 as well as top-line data read-outs later this quarter from our Phase 2b chronic migraine study and our multiple dose Phase 1 study evaluating quarterly self-injectable administration of ALD403,” said Randall C. Schatzman, Ph.D., president and chief executive officer of Alder. “In addition, we plan to initiate our next pivotal study, PROMISE 2, in the second half of 2016. As we continue our clinical momentum for ALD403, we will also continue to expand our team and establish a strong foundation to support a future FDA filing and ultimately commercialization to meet the critical unmet need of the 13 million patients who are migraine prevention candidates, including the three million patients suffering from chronic migraine.”
